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Abstract
RAP1, a component of the telomere-protective shelterin complex, has been shown to have
both telomeric and non-telomeric roles. In the liver, RAP1 is involved in the regulation of
metabolic transcriptional programs. RAP1-deficient mice develop obesity and hepatic stea-
tosis, these phenotypes being more severe in females than in males. As hepatic steatosis
and obesity have been related to increased liver cancer in mice and humans, we set out to
address whether RAP1 deficiency resulted in increased liver cancer upon chemical liver car-
cinogenesis. We found that Rap1-/- females were more susceptible to DEN-induced liver
damage and hepatocellular carcinoma (HCC). DEN-treated Rap1-/- female livers showed an
earlier onset of both premalignant and malignant liver lesions, which were characterized by
increased abundance of γH2AX-positive cells, increased proliferation and shorter telo-
meres. These findings highlight an important role for RAP1 in protection from liver damage
and liver cancer.
Introduction
Primary liver cancer is the fifth and seventh most common cancer in men and women, respec-
tively and the second leading cause of cancer-related death worldwide [1]. Hepatocellular car-
cinoma (HCC) represents approximately 90% of all cases of primary liver cancer [1]. The main
risk factors for HCC development include viral hepatitis, alcohol-induced hepatitis and non-
alcoholic steatohepatitis (NASH) [2]. The incidence of liver cancer is increasingly on the rise
and this is at least partly due to the growing epidemics of obesity and metabolic syndrome [3].
Mammalian telomeres are formed by TTAGGG repeats bound by a six-protein complex
known as shelterin, which ensures telomere protection. The shelterin complex is composed of
six core proteins, TRF1, TRF2, TIN2, POT1, TPP1 and RAP1 (for a review see [4–15]. Telo-
meres shorten with each cell division owing to the so-called “end-replication problem” [16,
17]. Telomerase activity can compensate for telomere shortening by the addition of de novo
TTAGGG repeats onto chromosome ends [18]. Telomerase is formed by a catalytic subunit
known as TERT and an associated RNA component or Terc that is used as template for the
addition of new telomeric repeats [18]. Telomerase is expressed in pluripotent stem cells;
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however, it is downregulated after birth in the majority of somatic tissues, contributing to telo-
mere shortening with aging [19]. Loss-of-function mutations in hTERT and hTERC are associ-
ated with familial liver diseases marked by fibrosis and inflammation [20, 21]. In addition,
telomere shortening has been shown to represent a causal factor impairing liver regeneration
and accelerating cirrhosis, a main risk factor for liver cancer development [22]. Indeed, telo-
mere shortening has been associated with cancer development in the liver [23–25]. Interest-
ingly, alterations in the expression of shelterin coding genes have also been identified in
cirrhosis and HCC, suggesting that the development of HCC involves the dysregulation of
telomere protective factors [26]. Mouse models deficient for shelterin genes have suggested a
role of shelterin proteins in HCC development [27, 28]. In particular, mice deficient for TRF1
in the liver, develop large liver cell changes (LLCC) frequently found in liver cirrhosis in
response to chronic replicative stress [28]. Similarly, transient depletion of the shelterin TRF2
in hepatocytes results in increased liver cancer [27]. These findings suggested that dysfunc-
tional telomeres can induce DNA damage and telomere aberrations in the liver, which in the
eventual loss of tumor suppressor genes such as p53, could lead to increased tumorigenesis
[29].
In addition, the telomerase gene has been also found mutated in human HCC. In particular,
whole-exome sequencing found a mutation hotspot in the telomerase (TERT) promoter, as
well as TERT focal amplification [30, 31]. Interestingly, TERT promoter mutations were found
at early HCC stages, pinpointing TERT as a key player in hepatocarcinogenesis by allowing the
immortalization of neoplastic clones [30]. Telomerase deficient mice are protected from HCC
development but present a significant increase of early stages neoplastic lesions as compared
to wild-type mice, indicating that telomere biology exerts a dual role in the initiation and pro-
gression of HCC [32–34].
RAP1 binds to telomeric repeats through its interaction with TRF2 [5, 35, 36]. Mouse RAP1
is not a key factor for telomere maintenance and protection in the presence of sufficient telo-
mere reserve but plays a crucial role in the context of telomerase deficiency [37–39]. RAP1 can
also bind throughout the chromosome arms where it regulates gene expression [37, 38, 40–
42]. Another non-telomeric function for RAP1 was revealed in the cytoplasm, where it acts as
a modulator of the NF-kB signaling pathway by interacting with IKK complex. The RAP1-IKK
interaction is required for the phosphorylation of the p65 subunit of NF-kB, enabling it to per-
form gene transcriptional activation [43]. RAP1-deficient mice do not have severe telomere
phenotypes and can live to adulthood; however, they develop hepatosteatosis and are prone to
obesity, being these phenotypes more severe in females than in males [40, 42]. Gene expression
profile analyses in liver of adult mice revealed that in the absence of RAP1 several metabolic
pathways including fatty acid metabolism, PPARα signalling and glucose metabolism are
remarkably affected [40]. PPARα (Peroxisome proliferator-activated receptor alpha) is a
ligand-activated transcription factor that belongs to the nuclear hormone receptor superfamily
and is a major regulator of hepatic energy control [44, 45]. Together with its cofactor PGC1α
(PPARγ Co-activator 1α), PPARα regulates the expression of genes involved in fatty acid beta-
oxidation, lipid metabolism, gluconeogenesis, inflammation, atherosclerosis and autophagy
[44–46]. In the absence of RAP1, PPARα and PGC1α levels are decreased leading to deregula-
tion of several of their target genes and the subsequent deregulation of metabolic pathways
involved in hepatic energy homeostasis. These molecular alterations are concomitant to
increased incidence of obesity, which similarly to that described for Pparα- and Pgc1α-defi-
cient mice [47–51], are more pronounced in RAP1-deficient females [40]. Of note, despite the
effect of RAP1-deficiency in obesity and on hepatosteatosis development, RAP1-deficient
mice do not spontaneously develop liver cancer. Indeed, no difference in tumor incidence has
been reported between Rap1+/+ and Rap1-/- mice, in both genders [40]. The role of the PPARα
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signalling in liver carcinogenesis is unclear. On one hand, PPARα-deficiency was shown to
enhance the susceptibility to DEN initiated HCC [52]. On the othe hand, loss of PGC1α was
shown to protect against DEN-induced liver cancer [53]. This role of RAP1 in regulating
important metabolic pathways in the liver [40, 42], may suggest a role for RAP1 in liver
cancer.
Here we analyze the role of RAP1 in DEN-induced carcinogenesis using both male and
female Rap1-/- mice. Similar to humans, a very pronounced gender disparity is observed in
mouse HCC models, males being more prone to develop HCC than females [54, 55]. We
found that Rap1-/- female mice were more susceptible to DEN-induced HCC than wild-type
controls as indicated by earlier onset and increased number of both pre-neoplastic lesions and
HCC, which was accompanied by a significantly decreased lifespan as the consequence of liver
cancer. Before humane end-point, DEN-induced female HCC lacking RAP1 showed increased
abundance of γH2AX, AC3 and Ki67 positive cells as well as shorter telomeres as compared to
wild-type control HCC, reflecting the higher proliferative history of RAP1-deficient tumors.
Results
DEN-induced liver damage hampers body weight gain as a consequence of
RAP1 deficiency
To investigate a potential role of RAP1 in protection from hepatocarcinogenesis, we induced
hepatocellular carcinoma (HCC) in both Rap1-/- and wild-type mice by intraperitoneal admin-
istration of diethylnitrosamine (DEN) [40, 56]. DEN is a DNA alkylating agent that, by induc-
ing DNA damage in the liver, eventually results in dysplastic foci (i.e. group of small dysplastic
hepatocytes with an increased nuclear/cytoplasmic ratio), which can progress to multifocal
HCC [57]. DEN was chosen at a concentration (25 mg /kg body weight) known to act as a
complete carcinogen if injected into 2-week-old mice when hepatocytes are still actively prolif-
erating [58, 59]. To address whether liver dysfunction associated to RAP1 deficiency synergizes
with DEN-induced liver lesions in HCC development, 2- week-old Rap1-/- and Rap1+/+ male
and female mice were injected with DEN (25 mg /kg body weight). The onset and progression
of liver lesions was monitored longitudinally by ultrasound analysis every fourth week from 28
weeks onwards after DEN treatment (Fig 1A). Groups of female mice from each genotype
were sacrificed at 40-, 45-, 55-, 60- and 65- weeks post-DEN treatment, for histopathological
analysis at shorter time-points. The rest of the mice were sacrificed when the presence of mas-
sive hepatic tumors was recognized as humane endpoint (Fig 1A).
To study the effects of DEN treatment on the previously described obesity phenotype of
RAP1-deficient mice, we followed body weight longitudinally in the different mouse cohorts
(Fig 1B and 1C). RAP1-deficient females treated with DEN showed a 10% increase in body
weight compared to the previously reported 30% increase in body weight in the case of
untreated Rap1-/- females (Fig 1B)[40, 42]. No differences in body weight were observed in the
case of the DEN-treated males (Fig 1C). In order to determine liver damage in the DEN treated
mice, we analyzed the plasma levels of alanine (ALT) and of aspartate (AST) aminotransferases
in males at 50 and 55 weeks post-DEN treatment and females at 50 and 60 weeks post-DEN
treatment (Fig 1D and 1E). We found that both male and female Rap1-deficient mice showed
significantly increased levels of ALT and AST compared to wild-type mice, indicating
increased liver damage in the absence of RAP1 (Fig 1D and 1E). Indeed, the ALT and AST lev-
els present in wild-type correspond to a grade 1 (51–125 U/L) while in RAP1-deficient males
and females to grade 2 (126–250 U/L) and 3 (251–500 U/L) of hepatotoxicity, respectively
[60].
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Fig 1. RAP1 deficiency leads to a higher susceptibility to DEN-induced liver damage and HCC development. (A) Two-
week-old Rap1+/+ and Rap1-/- female and male mice were intraperitoneally injected with DEN (25mg/kg body). Liver lesions
were longitudinally monitored by ultrasound analysis from 28 weeks onwards after DEN treatment every fourth week. A
group of Rap1+/+ and Rap1-/- females were sacrificed at 40-, 45-, 55-, 60- and 65 weeks post-DEN for histopathological
analysis. The rest of the mice were sacrificed at humane endpoint. (B-C) Body weight gain of Rap1+/+ and Rap1-/- females (B)
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Longitudinal ultrasound analysis of liver lesions showed a progressive increase in the total
volume of liver lesions per mouse in DEN-treated males and females (Fig 1F and 1G). Indeed,
RAP1-deficient females showed significantly larger liver lesions compared to wild-type females
(Fig 1F), while the differences between RAP1-deficient and wild-type males did not reach sta-
tistical significance (Fig 1G). Male mice presented an earlier onset and a more rapid tumor
growth than females, indicating a higher susceptibility of male mice for DEN-induced HCC as
already reported [54]. Interestingly, Rap1-/- females show a similar tumor volume as male mice
from week 52 onwards, in contrast to wild-type females that present significantly lower tumor
volume. These findings show an increased susceptibility of RAP1-deficient female mice to
DEN-induced liver carcinogenesis, in agreement with Rap1-/- females showing higher body
weight and higher hepatotoxicity in response to DEN than wild-type controls.
Finally, we followed the survival of the different mouse cohorts that died as a consequence
of liver tumors (Fig 2A and 2B). RAP1-deficient females presented a 15% decrease in median
survival compared with wild-type females (78 and 91.5 weeks post-DEN, respectively) (Fig
2A). In contrast, no differences in survival in the male cohorts were observed, being the
median survival of the Rap1+/+ and Rap1-/- male mice of 62 and 61 weeks post-DEN, respec-
tively (Fig 2B). The decreased survival of DEN-treated RAP1-deficient females as compared to
wild-type controls may be explained by their increased liver damage and more rapidly growing
liver lesions as detected by ultrasounds in response to the carcinogenic treatment.
RAP1 deficient females are more susceptible to DEN-induced HCC than
wild-type mice
To further analyze the tumor-prone phenotype of RAP1-deficient females in response to DEN,
we sacrificed a group of Rap1-/- and Rap1+/+ females at 40, 45–55 and 60–65 weeks post-DEN
treatment and performed full histopathological analysis of the livers. The lesions were catego-
rized as preneoplastic lesions and neoplastic lesions (Fig 3A). Preneoplastic lesions included α-
fetoprotein (AFP) positive foci, foci of altered hepatocytes (FAH), and hepatocellular adeno-
mas (HCA) [61, 62] (see Material and Methods). All the neoplastic lesions were HCC. We
found that 40-weeks post-DEN treatment, the number of preneoplastic lesions including AFP
& FAH as well as HCA was significantly higher in RAP1-deficient females compared to simi-
larly treated wild-type females (Fig 3B and 3C). Interestingly, we also found a significantly
increased number of HCC per cm2 of liver area in Rap1-/- females compared to Rap1+/+ con-
trols from 40 to 65 weeks post-DEN treatment (Fig 3D). Furthermore, the HCC burden (total
number of lesions of different size per mouse) in the entire liver was significantly higher in
Rap1-/- compared to Rap1+/+ females from 40 to 65 weeks post-DEN treatment (Fig 3E).
HCC can metastasize to the lungs [63]. We therefore set to quantify the number of lung
metastasis, by using an immunohistochemistry staining with the hepatocyte antigen (hep) in
and males (C) from the fifth week post-DEN onward. (D-E) Plasma levels analysis of alanine (ALT) and aspartate (AST)
aminotransferases in Rap1+/+ and Rap1-/- females at 50–60 weeks post-DEN (D) and males at 50–55 weeks post-DEN (E).
Females at 50- and 60- weeks post-DEN and males at 50- and 55- weeks post-DEN were grouped since no significant
differences were observed between these two ages. For ALT analysis, 5 Rap1+/+ and 6 Rap1-/- females at 50 weeks post-DEN
and 5 Rap1+/+ and 4 Rap1-/- females at 60 weeks post-DEN were analyzed. For AST analysis, 4 Rap1+/+ and 5 Rap1-/- females at
50 weeks post-DEN and 5 Rap1+/+ and 4 Rap1-/- females at 60 weeks post-DEN were analyzed. For ALT and AST analysis in
males, 4 Rap1+/+ and 2 Rap1-/- mice at 50 weeks post-DEN and 8 Rap1+/+ and 2 Rap1-/- mice at 55 weeks post-DEN were
analyzed. Hepatotoxicity grades are shown to the right. N, normal; G1, grade 1; G2, grade 2 and G3, grade 3. G1 hepatotoxicity
was defined as a serum ALT level of 51–125 U/L, G2 as a serum ALT level of 126–250 U/L and G3 as a serum ALT level of
251–500 U/L. (F-G) Quantification of total volume of hepatic lesion by ultrasound between 36- and 56-weeks post-DEN in
Rap1+/+ and Rap1-/- females (F) and males (G). Values and error bars represent the mean and SE, respectively. N, number of
mice. Statistical significance was determined by Student’s t test. �p<0.05, ��p<0.01, ���p<0.001; ns, not significant.
https://doi.org/10.1371/journal.pone.0204909.g001
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lung sections at 45–65 weeks post DEN treatment (Fig 3F). We found that 25% of RAP1-defi-
cient females present clusters of hep-positive cells in the lungs while none of the wild-type
females showed these lesions, indicating that RAP1 absence speeds up tumor spreading to the
lungs (Fig 3F).
Increased proliferation, DNA damage and apoptosis in HCC lacking RAP1
In order to address the molecular events underlying the increased neoplastic lesions in RAP1--
deficient females in response to DEN treatment, we set to analyze different molecular markers
in HCC at 50–55 weeks post-DEN treatment before humane end point. In particular, we mea-
sured proliferation (Ki67-positive cells), DNA damage (γH2AX-positive cells) and apoptosis
(AC3-positive cells) by immunohistochemistry in tumors from both wild-type and RAP1-defi-
cient females (Fig 4A–4F). We found that RAP1-deficient HCC showed a 2-fold increase in
Ki67-positive cells compared to wild-type HCC, in agreement with higher tumor growth rate
in Rap1-/- as compared to Rap1+/+ females (Figs 4A, 4B, 3D and 3E). RAP1-deficient HCC also
presented increased cells with DNA damage (γH2AX-positive cells) and increased apoptosis
compared to wild-type controls (Fig 4C–4F). The higher DNA damage burden in the RAP1--
deficient HCC may reflect either the higher susceptibility of Rap1-/- females to DEN-induced
hepatocarcinogenesis or the more advanced stages of RAP1-deficient tumors as compared to
wild-type controls at this time point.
Role of RAP1 in HCC telomere dynamics
Telomerase promoter mutations in human HCC highlight the importance of telomere length
maintenance for liver cancer [30, 31]. Here, we set to address whether RAP1-deficiency
impacted on telomere length in the context of DEN-induced liver carcinogenesis. To this end,
we analyzed telomere length in female liver sections at 40-weeks and in HCC at 60–65 weeks
post-DEN treatment before end-point, and in HCC at the humane endpoint from females at
70–100 weeks post-DEN (Fig 5A–5C). No significant differences were observed between
Rap1-/- and Rap1+/+ samples in either healthy liver tissue at 40 weeks or in HCC at the
Fig 2. RAP1 deficiency leads to a reduced lifespan of DEN-treated female mice. (A-B) Kaplan-Meier survival curves of Rap1+/+ and Rap1-/- female (A) and
male (B) mice. Statistical significance was determined by the log rank test. �, p� 0.05.); ns, not significant.
https://doi.org/10.1371/journal.pone.0204909.g002
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Fig 3. Earlier onset of premalignant and malignant hepatic lesions in DEN-treated Rap1-/- females. (A) Representative light microscopy images of α-
fetoprotein (AFP) and hematoxylin-eosin (H&E) liver sections showing the different types of lesions induced by DEN. Focus of AFP-positive hepatocytes, focus
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endpoint when tumors have reached maximal size between. In contrast, at 60–65 week post-
DEN treatment before humane end-point, we found that RAP1-deficient HCC showed both
decreased mean telomere intensity and decreased total nuclear telomere intensity (Fig 5A–
5C).
We also analyzed telomere length in male liver sections at 36-weeks and in HCC at the
humane endpoint from males that died at 55–65 or 65–75 weeks post-DEN (Fig 5D and 5E).
No significant differences were observed between Rap1-/- and Rap1+/+ samples in either
healthy liver tissue at 36 weeks or in HCC at the endpoint when tumors have reached maximal
size between (Fig 5D and 5E).
In accordance with previous work, these data confirm that RAP1 deficiency does not
impact on telomere length in healthy liver tissue, neither in females nor in males [40]. These
results also indicate that RAP1 deficiency does not have any effect in telomere length mainte-
nance in full blown HCC at the end-point, suggesting that telomere length is neither a driver
nor a limiting factor for tumor development and progression in these settings. In addition,
female and male HCCs present shorter telomeres as compared to cells in healthy liver tissue
indicating telomere shortening associated to malignant cell proliferation (Fig 5A–5E). The
observation that female HCCs at week 60–65 post-DEN before humane endpoint present
shorter telomeres as compared to wild type HCCs, probably reflects the proliferative history
and more advanced stages of Rap1-/- tumors as compared to Rap1+/+ controls (Fig 5A–5C).
Indeed, a RAP1-independent progressive telomere shortening is observed when comparing
HCCs before human endpoint to HCCs at human endpoint, both in Rap1+/+ and in Rap1-/-
female mice (Fig 5A–5C).
Discussion
RAP1 is part of the shelterin complex that protects telomeres [36]. Murine RAP1 does not
seem to be required for telomere capping and telomere length maintenance under normal
conditions [37, 39, 64]. However, we recently showed that RAP1 is important for telomere
length maintenance in the context of cellular stress conditions such as telomerase deficiency
[64]. In addition, we previously showed that RAP1 can associate to non-telomeric genomic
sites where it regulates gene expression [37, 38, 40–42]. RAP1-deficient mice are obese and
develop signs of metabolic syndrome, including liver steatosis, which are more acute in
females. [40, 42]. This is accompanied by altered gene expression profiles affecting several met-
abolic pathways [40]. As metabolic syndrome and obesity has been associated with increased
liver cancer [2, 3, 65, 66], here we set to address whether RAP1 deficiency resulted in increased
liver cancer in response to treatment with a widely used carcinogen, DEN. We found increased
liver damage and increased tumor susceptibility of RAP1- deficient as compared to wild type
female mice. Indeed, Rap1-/- females showed increased number of both premalignant and
malignant lesions and the tumors more rapidly reached larger sizes leading to significantly
decreased Rap1-deficient female mouse survival upon DEN treatment. In addition, Rap1-/-
female HCC metastasized to the lung at earlier time-points than wild-type HCC, also indicat-
ing that Rap1-/- females are more susceptible to DEN-induced hepatocyte malignization. These
of altered hepatocytes (FAH), hepatocellular adenoma (HCA) and hepatocellular carcinoma (HCC) are shown from left to right. For a detailed histological
description see Material and Methods. (B-C) Quantification of FAHs and AFP-positive foci (B) and HCAs (C) in Rap1+/+ and Rap1-/- livers of female mice at 40
weeks after DEN injection. (D) Quantification of total number of HCC in Rap1+/+ and Rap1-/- livers of female mice at 40, 45–55 and 60–65 weeks post-DEN. (E)
Quantification of the number of HCC of different size in the mice described in (D). (F) Incidence of lung metastasis in Rap1+/+ and Rap1-/- female mice between
45 and 65 weeks post-DEN. A representative light microscopy image of hepatocyte antigen-stained lung sections is shown to the right. Values and error bars
represent the mean and SE, respectively. N, number of mice. Statistical significance was determined by Student’s t test.
https://doi.org/10.1371/journal.pone.0204909.g003
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observations are in agreement with a more prominent effect of RAP1-deficiency in fat accu-
mulation in female mice [40, 42].
Non- alcoholic fatty liver disease (NAFLD) is a well-known risk factor for HCC develop-
ment [3, 65, 66]. NAFLD is characterized by increased hepatic lipid accumulation and dimin-
ished ability of the liver to metabolize several substrates. NAFLD progress to NASH, in which
hepatocyte metabolic stress induces cell death, production of damage-associated molecules
and chronic inflammation [65, 67]. Differentiated hepatocytes are able to re-enter the cell
cycle and replace damaged cells and therefore the liver has the ability to repair itself after acute
damage [68]. However, in chronic necro-inflammation, constant cell death, compensatory
regeneration and activation of non-parenchymal cells, together with an altered immune
response, promote liver fibrosis and tumorigenesis [65]. Necroinflammation also induces rep-
licative stress, DNA damage and genetic instability that is detectable in preneoplastic lesions
[69]. Our data indicate that the role of RAP1 in hepatocarcinogenesis is mediated by its func-
tion in metabolism regulation rather than to its telomeric function. Indeed, RAP1 has no effect
in male hepatocarcinogenesis while it does in females in which RAP1 role in fat accumulation
is predominant [40, 42]. Although a RAP1 telomeric function cannot be ruled out, our data
underlines that the effect of RAP1 deficiency in NAFLD development synergizes with DEN-
induced liver damage resulting in a faster HCC development in female mice lacking RAP1.
Material and methods
Mice generation and handling
All mice were generated and maintained at the Animal Facility of the Spanish National Cancer
Research Centre (CNIO) under specific pathogen-free conditions in accordance with the rec-
ommendation of the Federation of European Laboratory Animal Science Associations
(FELASA). Rap1+/+ and Rap1-/- mice were generated by mating heterozygous (Rap1+/-) males
and females [40]. Food (Harlan Laboratories) and water were provided ad libitum and mea-
surements of the body weight were performed monthly. All animal experiments were
approved by the Ethical Committee (CEIyBA) (IACUC.015-2014, CBA_21_2014) and per-
formed in accordance with the guidelines stated in the International Guiding Principles for
Biomedical Research Involving Animals, developed by the Council for International Organiza-
tions of Medical Sciences (CIOMS).
Mice included in the survival study were monitored two or three times per week. After the
detection of the first tumor by ultrasounds, mice were monitored daily. We applied humane
endpoint criteria and euthanized the animals when they showed signs of pain, sickness, suffer-
ing, or moribund conditions. In particular: loss of body weight, presence of big abdominal
masses, reduced mobility, and hunched body posture were used as main criteria to recognize
humane endpoint. When mice reached endpoint criteria, they were euthanized within a maxi-
mum of 24h. Euthanasia was performed in a CO2 gas chamber. Two of the twenty-six mice
included in the survival study died unexpectedly before showing criteria for euthanasia. In
both cases necropsy was performed and the presence of massive hepatic tumors was recog-
nized as the cause of death.
Fig 4. Increased proliferation, DNA damage and apoptosis in HCC lacking RAP1 in females. (A-F) Representative images and
quantification of Ki67 (A, B) γH2AX (C-D) and AC3-positive cells (E-F) in Rap1+/+ and Rap1-/- tumor sections of female mice at
50–55 weeks post-DEN treatment. Tumors from 6 Rap1+/+ and 6 Rap1-/- females were analyzed. Three females from each cohort
were at 50- and three at 55- weeks post-DEN. Mice of 50 and 55 weeks post-DEN were grouped since no significant differences were
observed between these two ages. The size of the analyzed tumors ranged from 5 to 20 mm2. Values and error bars represent the
mean and SE, respectively. N, number of tumors. Statistical significance was determined by Student’s t test. �p<0.05, ��p<0.01,
���p<0.001.
https://doi.org/10.1371/journal.pone.0204909.g004
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Tumor induction and serum analysis
Fourteen-day-old mice were injected intraperitoneally with 25 mg/kg of DEN (Sigma) [56].
Serum ALT and AST levels were determined using ABX Pentra (Horiba Medical).
Ultrasound imaging and tumor quantification
Animals were anesthetized with Isofluorane (Isovet, Braun Vetcare) (4% during anesthetic
induction and 2% as maintenance level) and livers were scanned (Vevo 770, 40 Mhz fre-
quency) for structural alterations, including echogenicity variations, by using the probe
RMV707b (Visualsonics, Canada). The frame rate used is in the range of 60 Hz and 11X11
mm FOV (field of view). The three diameters dimensions were measured (width, W, length,
L, and depth, D) and the tumor volume was calculated by using the formula V = π/6xWxLxD
[70].
Hepatotoxicity grading
Criteria based on the World Health Organization Adverse Reaction Terminology (WHO-
ART) were utilized to grade hepatotoxicity. Grade 1 hepatotoxicity was defined as a serum
ALT level of 51–125 IU/L, or 1.25–2.5 times normal; grade 2 as a serum ALT level of 126–250
IU/L, or 2.6–5.0 times normal; grade 3 as a serum ALT level of 251–500 IU/L [60]
Immunohistochemistry analysis
Tissue samples were fixed in 10% buffered formalin, dehydrated, embedded in paraffin wax
and sectioned at 2.5 mm. Slides were deparaffinized in xylene and re-hydrated through a series
of graded ethanol until water. Serial sections were stained with hematoxylin and eosin for
pathological examination and lesions quantification. Serial paraffin sections of liver and lung
samples were analyzed. The classification of the hepatic lesions was performed by a trained
pathologist in a blinded manner.
Immunohistochemistry was performed on de-paraffined liver or lung sections processed
with 10 mM sodium citrate (pH 6.5) cooked under pressure for 2 min. Slides were washed in
water, then in Buffer TBS Tween20 0.5%, blocked with peroxidase, washed with TBS Tween20
0.5% again and blocked with fetal bovine serum followed by another wash. The liver slides
were incubated with the primary antibodies: goat polyclonal to alpha-fetoprotein (R&D sys-
tems), mouse monoclonal to phospho-Histone H2AX (ser139) (JBW301, Millipore), rabbit
monoclonal to Ki-67 (D3B5, Cell Signaling) or rabbit polyclonal to C3 cleaved-caspase 3
(Asp175) (Cell Signaling); the lung slides were incubated with the primary antibody: mouse
monoclonal to human hepatocytes (OCH1E5, DAKO). Slides were then incubated with sec-
ondary antibodies conjugated with peroxidase from DAKO. Sections were lightly
Fig 5. RAP1 deficiency does not affect telomere length in full blown HCC. (A-B) Mean telomere fluorescence (A) and total nuclear telomere
fluorescence (B) in liver sections at 40 weeks post-DEN, 60–65 weeks post-DEN and at the endpoint at 70–100 weeks post-DEN. At 40 weeks the
telomere intensity was determined in healthy hepatic tissue. At 60–65 weeks post-DEN before humane endpoint and at the humane endpoint,
telomere intensity was determined in HCC. At 60–65 weeks post-DEN, the tumors analyzed presented an area between 10–30 mm2. At the endpoint,
the analysis was performed in tumors with an area between 50–500 mm2. (C) Representative Q-fish images showing the telomere FISH (red) in Rap1+/
+ and Rap1-/- liver and tumor sections of female mice at different time points. (D-E) Mean telomere fluorescence (D) and total nuclear telomere
fluorescence (E) in liver sections at 36 weeks post-DEN and at the humane endpoint of male mice that died of liver tumors at either 55–65 or 65–75
weeks post DEN. At 36 weeks the telomere intensity was determined in healthy hepatic tissue. At the humane endpoint, telomere intensity was
determined in HCC. In male mice at humane end points ranging from 55–65 or from 65–75 weeks post-DEN, the tumors analyzed presented an area
between 50–350 mm2 and 100–500 mm2, respectively. a.u.f., arbitrary units of fluorescence. Values and error bars represent the mean and SE,
respectively. N, number of tumors. Statistical significance was determined by Student’s t test. �p<0.05, ��p<0.01, ���p<0.001.
https://doi.org/10.1371/journal.pone.0204909.g005
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counterstained with hematoxylin and analyzed by light microscopy. Pictures were taken using
Olympus AX70 microscope. The percentage of positive cells was quantified by eye.
Liver lesions were classified as follows. α-fetoprotein (AFP) positive foci are composed of
hepatocytes positive for AFP with a cytosolic staining pattern. AFP is known to be expressed
in early liver development and during hepatocarcinogenesis, but is largely absent in normal
adult liver. AFP expression takes place during the early stages of hepatocarcinogenesis, before
the appearance of histologically evident transformation, although not all HCC developed in
mice are AFP positive [71]. Foci of altered hepatocytes (FAH) are composed of hepatocytes
with increased cytoplasmic basophilia due to polyribosomes or rough endoplasmic reticulum,
often smaller than normal, characterized by a high nuclear to cytoplasmic ratio that results in a
“crowded” appearance. Eosinophilic cytoplasmic inclusions are frequently found within the
hepatocytes in FAHs [61, 62]. Hepatocellular adenoma (HCA) are well-circumscribed lesions
often causing compression of the adjacent parenchyma. The liver lobular architecture is not
maintained, causing an irregular growth pattern that represents a primary distinction between
HCA and FAH. Hepatocytes in HCA are well differentiated and variable in size, occasionally
contain eosinophilic cytoplasmic inclusions. Degenerative changes such as lipidosis and cystic
degeneration are frequently observed [61, 62]. Hepatocellular carcinoma (HCC) consist of
demarcated masses with irregular borders due to the cellular invasion of the surrounding tis-
sue. The lobular architecture is not maintained and the typical trabecular, glandular or solid
growth patterns are observed. HCC are characterized by severe cellular polymorphism with
enlarged and hyperchromatic nuclei and contain abundant mitotic figures. The masses are
often characterized by presence of various size cysts, and hemorrhagic and/or necrotic areas
[61, 62].
Telomere length quantitative fluorescence (Q-Fish) analyses on liver
sections
For quantitative telomere fluorescence in situ hybridization (Q-FISH), paraffin-embedded sec-
tions were deparaffinized and fixed with 4% formaldehyde, followed by digestion with pep-
sine/HCl and a second fixation with 4% formaldehyde. Slides were dehydrated with increasing
concentrations of EtOH (70%, 90%, 100%) and incubated with the telomeric probe for 3 min
at 85˚C followed by 2h RT incubation in a wet chamber. In the final steps, the slides were
extensively washed with 50% formamide and 0.08% TBS-Tween [72]. Confocal microscopy
was performed at room temperature with a laser-scanning microscope (TSC SP5) using a Plan
Apo 63Å-1.40 NA oil immersion objective (HCX). Maximal projection of z-stack images gen-
erated using advanced fluorescence software (LAS) were analyzed with Definiens XD software
package. The DAPI images were used to detect telomeric signals inside each nucleus.
Statistical analysis
The Kaplan-Meier method was used to estimate survival curves and log rank was used to eval-
uate statistical differences in median survival of the different mouse cohorts. A Student t-test
was used to calculate the statistical significance (p) (p� 0.05 = � and p� 0.01 = ��) in body
weight, enzyme levels in serum, tumor burden, number of lesions, ki67, γH2AX and cleaved-
caspase-3 expression. A chi-square test was used to calculate statistical differences in lung
metastasis incidence.
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